JP2015514797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514797A5 JP2015514797A5 JP2015507634A JP2015507634A JP2015514797A5 JP 2015514797 A5 JP2015514797 A5 JP 2015514797A5 JP 2015507634 A JP2015507634 A JP 2015507634A JP 2015507634 A JP2015507634 A JP 2015507634A JP 2015514797 A5 JP2015514797 A5 JP 2015514797A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- extract
- terminaria
- elliptica
- metabolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 241000464908 Elliptica Species 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims 1
- 229920002079 Ellagic acid Polymers 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002852 ellagic acid Drugs 0.000 claims 1
- 235000004132 ellagic acid Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636792P | 2012-04-23 | 2012-04-23 | |
| US61/636,792 | 2012-04-23 | ||
| PCT/IB2013/053155 WO2013160811A1 (en) | 2012-04-23 | 2013-04-22 | Composition for treating metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514797A JP2015514797A (ja) | 2015-05-21 |
| JP2015514797A5 true JP2015514797A5 (enExample) | 2016-05-26 |
Family
ID=49482298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507634A Pending JP2015514797A (ja) | 2012-04-23 | 2013-04-22 | 代謝障害治療用組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150290265A1 (enExample) |
| EP (1) | EP2841080A4 (enExample) |
| JP (1) | JP2015514797A (enExample) |
| KR (1) | KR20150003862A (enExample) |
| CN (1) | CN104244962A (enExample) |
| AU (1) | AU2013254329A1 (enExample) |
| BR (1) | BR112014026326A2 (enExample) |
| CA (1) | CA2870907A1 (enExample) |
| IL (1) | IL235317A0 (enExample) |
| IN (1) | IN2014MN02269A (enExample) |
| MX (1) | MX2014012742A (enExample) |
| NZ (1) | NZ701133A (enExample) |
| RU (1) | RU2014145931A (enExample) |
| SA (1) | SA113340494B1 (enExample) |
| TW (1) | TW201343174A (enExample) |
| WO (1) | WO2013160811A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3233188A4 (en) * | 2014-12-19 | 2018-11-07 | Halo Life Science, LLC | Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels |
| MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
| EP3566055B1 (en) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd inhibitor for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| KR20200108015A (ko) | 2018-01-10 | 2020-09-16 | 브라이트씨드, 인크. | 대사를 조절하기 위한 방법 |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| MX2022005682A (es) | 2019-11-11 | 2022-08-08 | Brightseed Inc | Extracto, producto consumible y método para enriquecer metabolito bioactivo en un extracto. |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| KR102408566B1 (ko) * | 2020-04-09 | 2022-06-16 | 대한민국 | 터미날리아 비아라타 추출물을 이용한 피부 주름 개선용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005053864A (ja) * | 2003-08-06 | 2005-03-03 | Ryukyu Bio Resource Kaihatsu:Kk | 糖尿病疾患予防・治療剤 |
| JP2006188486A (ja) * | 2004-12-07 | 2006-07-20 | Toyo Shinyaku:Kk | 体脂肪蓄積抑制または低減剤 |
| AU2005328179A1 (en) * | 2005-02-23 | 2006-08-31 | Avesthagen Limited | Plant extracts and methods and uses therefore |
-
2013
- 2013-04-22 CN CN201380021515.3A patent/CN104244962A/zh active Pending
- 2013-04-22 MX MX2014012742A patent/MX2014012742A/es unknown
- 2013-04-22 US US14/391,762 patent/US20150290265A1/en not_active Abandoned
- 2013-04-22 NZ NZ701133A patent/NZ701133A/en not_active IP Right Cessation
- 2013-04-22 EP EP13781126.1A patent/EP2841080A4/en not_active Withdrawn
- 2013-04-22 IN IN2269MUN2014 patent/IN2014MN02269A/en unknown
- 2013-04-22 RU RU2014145931A patent/RU2014145931A/ru unknown
- 2013-04-22 CA CA 2870907 patent/CA2870907A1/en not_active Abandoned
- 2013-04-22 KR KR20147032772A patent/KR20150003862A/ko not_active Withdrawn
- 2013-04-22 BR BR112014026326A patent/BR112014026326A2/pt not_active IP Right Cessation
- 2013-04-22 AU AU2013254329A patent/AU2013254329A1/en not_active Abandoned
- 2013-04-22 TW TW102114264A patent/TW201343174A/zh unknown
- 2013-04-22 JP JP2015507634A patent/JP2015514797A/ja active Pending
- 2013-04-22 WO PCT/IB2013/053155 patent/WO2013160811A1/en not_active Ceased
- 2013-04-23 SA SA113340494A patent/SA113340494B1/ar unknown
-
2014
- 2014-10-23 IL IL235317A patent/IL235317A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514797A5 (enExample) | ||
| RU2014145931A (ru) | Композиция для лечения нарушений метаболизма | |
| JP2014533680A5 (enExample) | ||
| WO2013022278A3 (en) | N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
| WO2009008006A3 (en) | Pharmaceutical compositions for gastrointestinal drug delivery | |
| JP2012193216A5 (enExample) | ||
| JP2012520343A5 (enExample) | ||
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| JP2015057451A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| CR10455A (es) | Compuestos farmaceuticos | |
| CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
| JP2015083580A5 (enExample) | ||
| IL292465B2 (en) | Neuroactive compounds and methods of use thereof | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| JP2012517449A5 (enExample) | ||
| WO2010092450A8 (en) | Stable pharmaceutical composition for atherosclerosis | |
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| WO2013022279A3 (en) | N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
| JP2016530291A5 (enExample) | ||
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| PH12014502802B1 (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient |